

ASX ANNOUNCEMENT

DATE: 21 April 2020

VIRTUS HEALTH LIMITED (ASX: VRT)

COVID-19 IMPACT UPDATE – VIRTUS HEALTH RESUMES IVF TREATMENT

Virtus Health Limited (ASX “VRT”) supports today’s decision by the Australian Federal Government to lift the suspension on elective surgery, including Assisted Reproductive Services (“ARS”) and is pleased to confirm it has introduced COVID-19 testing for patients.

- Australia – Virtus Health clinics in Australia will resume fertility services and ARS treatment from 27 April with increased infection control and safety protocols.

For social distancing reasons, fertility specialists will continue telehealth consulting via phone or online video conferencing through our Fertility Link service but where appropriate, personal consultations will be possible.

- Australian Day Hospitals - Virtus Health will resume ARS procedures and non-IVF elective surgery including laparoscopic gynaecology procedures, endoscopy and other procedures across our seven day hospitals.
- Australian Diagnostics – throughout the elective surgery suspension, Virtus Health diagnostic and pathology services maintained testing and screening services at reduced capacity. Diagnostics will begin to increase staffing and services as ARS operations return to normal levels and demand for diagnostics rises.
- Singapore – due to Singapore’s continued low community transmission, Virtus Health’s Singapore clinic, the Virtus Fertility Centre, has remained open.
- Europe – the Trianglen Fertility Clinic in Copenhagen, Denmark reopened on 20 April 2020 and will operate seven days a week, following Danish Government approval for resumption of provision of health services. Our second facility in Denmark, Aagaard, is scheduled to return to work in the coming days.

All Virtus clinics in Ireland and the United Kingdom remain closed. Fertility specialists in these regions continue to utilise telehealth consultations to facilitate the continuity of care and treatment for patients in preparation for when the lockdown is lifted.

Kate Munnings, Virtus Health Group CEO said, “Our Australian patients have been eagerly awaiting today’s decision”.

“With the suspension lifted, it means women and couples that need assistance in order to conceive can now restart treatment. We are pleased the Government recognise the needs of ARS patients and their desire to have a family.

"At Virtus Health, patient safety is our priority; we are introducing COVID-19 testing for patients where appropriate in consultation with their fertility specialist, with a 24 hour test turnaround time for results," said Ms Munnings.

Authorised by the Board of Directors of Virtus Health.

ENDS

Further information:

Kate Munnings

CEO

Virtus Health

+61 (0)2 9425 1722

Angela Read

PR and Media Specialist

Virtus Health

+61 (0)428 448 719

angela.read@virtushealth.com.au

About Virtus Health Limited

Virtus Health Limited (ASX:VRT) brings together leading clinicians, scientists, researchers and support staff to provide the very best in fertility care and related specialised diagnostic and day hospital services. We have developed one of the most successful medical collaborations in the world. With 127 of the world's leading fertility specialists supported by over 1300 professional staff, we are the largest network and provider of fertility services in Australia and Ireland, with a growing international presence in the UK, Denmark and Singapore.